0102030405
Tirzepatide Dual GLP-1 uye GIP Receptor Agonist yeWeight Management uye Glycemic Control
Tsanangudzo Yakadzama
Tirzepatide mushonga mutsva unoshandiswa kwenguva refu uremu manejimendi muvarwere vakafuta vane kufutisa kwevanhu vakuru kana huremu hunoenderana nehuremu. Iyo glucose-inotsamira agonist yeglucagon polypeptide (GIP) uye glucagon-yakafanana peptide-1 (GLP-1) receptors. Yakatenderwa neFDA muna 2022, tirzepatide inosanganisa mhedzisiro yeaviri enteric proinsulins kuita imwe molecule, inosimudzira insulin secretion uye kuderedza glucagon mazinga. Ichi chinyorwa chinoongorora maitiro echiito, kiriniki efficacy, uye chengetedzo nhoroondo yetirzepatide seye adjunctive therapy yekurasikirwa nekurema uye yakagadziridzwa glycemic control kune varwere vane Type 2 chirwere cheshuga.
I. Kunzwisisa Tirzepatide:
A. Glucose-inotsamira agonist yeGIP uye GLP-1 receptors
B. Mechanism yekuita: kuwedzera chikamu I uye chikamu II insulin secretion, kuderedza glucagon
II. Kushandiswa Kwekiriniki uye Mvumo yeFDA:
A. Chiratidzo: Kureba kwenguva refu kwekugadzirisa uremu muvarwere vakafuta vane uremu hwevakuru kana huremu hunoenderana nehuremu
B. Adjunctive therapy yekuvandudza glycemic control kune vanhu vakuru vane chirwere cheshuga chechipiri
C. FDA mvumo uye kushambadzira naEli Lilly muna 2022
III. Efficacy mu Weight Management:
A. Kuenzanisa kushanda:
Muzana wekurasikirwa uremu: Yakaderera-dose (5mg), yepakati-dose (10mg), uye yakakwirira-dose (15mg) mapoka
Avhareji yekurasikirwa nehuremu muzana mumapoka akasiyana ezviyero
Kuenzanisa neboka re placebo
Percentage yezvidzidzo vanowana uremu kupfuura 20%
B. Kuchengetedzwa profiles: Frequency of adverse reactions zvichienzaniswa ne placebo group
C. Kuenzanisa nemimwe mishonga yekuderedza uremu:
Orlistat (pamusoro-the-counter): Musiyano mukuremerwa uremu muzana
IV. Mechanism yeGlycemic Control uye Kurasikirwa Kwehuremu:
A. Kuita kweGLP-1 uye GIP receptors
B. Kudzvinyirirwa kwechido uye kuderedzwa kwekudya kwekudya
Tirzepatide, seyakaviri GLP-1 uye GIP receptor agonist, inopa huremu huremu manejimendi uye yakagadziridzwa glycemic control muvarwere vakafuta vane kufutisa kana kurema-ane hukama necomorbidities, pamwe chete nevanhu vane Type 2 chirwere cheshuga. Iyo glucose-inotsamira nzira yekuita inosimudzira insulin secretion uye inoderedza mazinga eglucagon. Nekuremerwa uremu muzana uye yakanaka kuchengetedza chimiro, tirzepatide inomira pachena semushonga une simba wekureba uremu manejimendi. Kumwe kutsvagisa uye zvidzidzo zvekiriniki zvichaenderera mberi nekuongorora zvingangobatsira uye mashandisirwo emushonga uyu unovimbisa.
Kuti tipe zvirinani zvekutengesa ruzivo, isu tinokwanisa kugadzirisa iyo capsule uye zvigadzirwa zvemvura, zvinoenderana nezvinodiwa zvinongedzo.
Tinogona kugadzirisa kuyerwa: 500mg/capsule, 550mg/capsule, 600mg/capsule.
Tinogona kugadzirisa kurongedza: 60 caps / bhodhoro, 90 caps / bhodhoro, 120 caps / bhodhoro.
Isu tinokwanisa kugadzirisa capsule shells uye mavara: chirimwa capsule shells, gelatin capsule shells.
Tsanangudzo
